Inflammatory bowel disease complicating with pancreatic abnormalities: a single center analysis
10.3760/cma.j.issn.1674-1935.2018.03.012
- VernacularTitle:炎症性肠病合并胰腺病变单中心分析
- Author:
Xiangguo SHEN
1
;
Duowu ZOU
;
Zhaoshen LI
;
Can XU
Author Information
1. 第二军医大学长海医院消化内科
- Keywords:
Inflammatory bowel disease;
Crohn disease;
Colitis,ulcerative;
Pancreatic diseases
- From:
Chinese Journal of Pancreatology
2018;18(3):193-195
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the inflammatory bowel disease (IBD) complicating with pancreatic abnormalities in China.Methods A retrospective analysis for clinical data of 592 IBD cases hospitalized in Changhai hospital from June 2009 to May 2017 were conducted,and the incidence of ulcerative colitis (UC) and Crohn disease (CD) complicating with pancreatic abnormalities was analyzed.Cases were divided into two groups according to whether anti TNF-α bodies therapy for treating IBD was given,and the incidence of acute pancreatitis (AP) in UC and CD patients complicating with pancreatic abnormalities was compared.Results There were 2 patients with pancreatic abnormalities in 310 CD cases including one with AP and pancreatic cystic lesions(PCL),and one with PCL.There were a total of 14 patients with pancreatic abnormalities in 282 UC cases including 4 cases with AP,4 cases with chronic pancreatitis (CP),4 cases with pancreatic cancer (PC),one case with CP and PC and one case with type 2 autoimmune pancreatitis (AIP).The incidence of pancreatic abnormalities in UC was significantly higher than that in CD (P ＜0.01).No AP happened (0/62) in patients receiving anti TNF-α bodies therapy.There were 5 AP cases in patients without anti TNF-α bodies therapy group (5/449),and the difference was not statistical significant.Conclusions UC is more closely associated with pancreatic abnormalities,especially CP and PC.Whether anti TNF-αtherapy could decrease the AP risk in IBD patients has not yet been determined.
